Clinical trials have reported significant reductions in inflammatory biomarkers, including CRP, TNF-α, IL-6, and interleukin-1β (IL-1β), following treatment with dulaglutide, liraglutide, and exenatide in patients with T2D [127,128,129,130,131]. This evidence concerns the gene IL1B and type 2 diabetes mellitus.